Cancer, Neurology Drugs Lead 2020 Pharma Pipeline

In its quarterly drug pipeline trends report, OptumRx projected that 2020 will see large numbers of drug approvals for oncology drugs and identified 11 drugs with the potential to be blockbusters in the United States.

OptumRx, which is owned by UnitedHealth Group, sorted the drugs likely to be approved this year into 17 treatment categories. Cancer-treating drugs were by far the most prevalent, with 44 likely approvals. Neurology followed with 29.

© 2024 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

humana-logo-on-smartphone
February 22

CenterWell Pharmacy Exec: New App Targets Digitally Savvy Seniors

READ MORE
part-d-document-with-stethoscope
February 22

Part D ‘Copay Smoothing’ Rollout Might Be Bumpy, Some Experts Warn

READ MORE
pharmacist-looking-up-drug-information
February 22

Preventive Drug Lists Can Boost Workers’ Health, Study Suggests

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today